ABT-126 is a nicotinic acetylcholine receptor (nAChR) agonist that is selective for the α7 subtype of the receptor. nAChRs are thought to play a role in a variety of neurocognitive processes and have been a pharmacologic target for disorders with cognitive impairment, including schizophrenia and Alzheimer's disease. As part of the preclinical safety package for ABT-126, its potential for abuse was assessed. While the involvement of the α4β2 subtype of the nicotinic receptor in the addictive properties of nicotine has been demonstrated, the role of the α7 receptor has been studied much less extensively. A number of preclinical assays of abuse potential including open-field, drug discrimination and self-administration were employed in male rats. ABT-126 had modest effects on locomotor activity in the open-field assay. In nicotine and D-amphetamine drug discrimination assays, ABT-126 administration failed to produce appreciable d-amphetamine-like or nicotine-like responding, suggesting that its interoceptive effects are distinct from those of these drugs of abuse. In rats trained to self-administer cocaine, substitution with ABT-126 was similar to substitution with saline, indicating that it lacks reinforcing effects. No evidence of physical dependence was noted following subchronic administration. Overall, these data suggest that ABT-126 has a low potential for abuse. Together with other literature on this drug class, it appears that drugs that selectively activate α7 nAChRs are not likely to result in abuse or dependence.
Introduction
Acetylcholine (ACh) produces its pharmacological effects via two classes of receptors, metabotropic and ionotropic ACh receptors. Ionotropic Ach receptors were originally identified by their ability to bind nicotine, thus they are known as nicotinic receptors. The majority of nicotinic receptors are heteropentamers, formed by combinations of up to 7 distinct α and 3 distinct β subunits, resulting in a multiplicity of receptor subtypes. Unlike the heteropentameric nicotinic receptors, however, the α7 receptor subtype is comprised of homomeric pentamers, a property shared by only one other nAChR subtype, the α8 receptor (McGehee and Role,1995; Gerzanich et al., 1994) . The α7 pentamer forms a ligand-gated Ca 2 + ion channel that rapidly desensitizes when activated (Palma et al., 1996; Revah et al., 1991; Yu and Role, 1998) , and the rate of desensitization can be ligand-and distributiondependent (Wooltorton et al., 2003) . α7 receptors are widely distributed throughout cortical and subcortical regions of brain, with prominent expression in hippocampal and frontal-cortical regions, suggesting modulatory effects upon cognitive function (Hogg et al., 2003; Paterson and Nordberg, 2000) . Preclinical studies with selective agonists of the α7 nAChR suggest cognition-enhancing effects across a broad range of animal models (Bitner et al., 2013; Levin et al., 1999; Sydserff et al., 2009; Gurley et al., 2009; Haydar and Dunlop, 2010) . Furthermore, evidence exists for neuro-protective effects of agonists of the α7 nAChR (Egea et al., 2007; Mudo et al., 2007; Shimohama, 2009) , indicating potential utility in neurodegenerative diseases.
Nicotine is a non-selective nicotinic receptor agonist that has well known addictive properties (Balfour, 2009) as it activates many of the same brain regions as other drugs of abuse, such as cocaine (Zernig et al., 1997) . While research during the past few decades has implicated the α4 and β2 subunit-containing receptors in the formation and maintenance of nicotine addiction (Picciotto et al., 1998; Tapper et al., 2004; Kenny and Markou, 2001) , the role of the α7 receptor in nicotine addiction has remained poorly defined. Assessment of the rewarding or dependence-producing effects of nicotine in the α7 knockout mouse has been addressed by a number of laboratories, with results which suggest perhaps a modulatory role of the receptor in nicotine dependence (Levin et al., 2009; Salas et al., 2004; Harenza et al., 2014) . These data come with the typical caveat that developmental adaptation in the absence of the receptor may make generalizations difficult. Perhaps a more direct approach to the question of whether the α7 nAChR is involved in nicotine reward or dependence, and indeed, whether agonists of this receptor possess addictive properties in the absence of stimulation of other nicotinic receptor subtypes, would be to examine the discriminative and reinforcing effects of a highly selective α7 nAChR agonist in normal animals with intact cholinergic receptors. To the best of our knowledge, these potential properties of selective α7 nAChR agonists have not yet been extensively studied.
ABT-126 (1R,4R,5S)-4-(5-Phenyl-[1,3,4]thiadiazol-2-yloxy)-1-azatricyclo [3.3.1.13,7] decane is an α7 nAChR agonist. It possesses high binding affinity (Ki = 11-14 nM) at mouse, rat and human α7 nAChR, and has been shown to display 74% maximal agonist activity at the human form of the receptor (Bitner et al., 2013) . ABT-126 is highly selective for the α7 nicotinic receptor subtype, and in a panel of radioligand assays to examine promiscuity of binding, it had only modest affinity for one off-target site: the serotonin 5-HT3 receptor, where it is an antagonist, with 10-fold less potent binding affinity than at the α7 nAChR. It has good bioavailability across a number of routes of administration and readily distributes to the brain (Gopalkrishnan, 2016) . ABT-126 demonstrated efficacy in rodent and primate animal models relevant to Alzheimer's disease (AD) and cognitive impairment associated with schizophrenia (CIAS) (Gopalkrishnan, 2016) , and it has been evaluated in a number of clinical trials for cognitive disorders Othman et al., 2014) .
During the course of clinical development, drugs with CNS activity must be evaluated for the potential for abuse so that they can be appropriately scheduled by regulators (Mansbach et al., 2003; Markgraf et al., 2015) . If the drug operates upon pathways known to be associated with abused drugs and/or has stimulant or sedative effects, then a careful evaluation of its potential for abuse is required, which includes comparison to known drugs of abuse that operate within the same pathway. If the drug is being developed for an indication for which other medications exist which have the potential for abuse, then these medications should also be used as comparators. In the case of ABT-126, an abuse potential assessment required comparison to nicotine itself. However, in considering other drugs used to treat cognitive disorders (e.g., ADHD), comparison to psychomotor stimulants was also considered to be warranted. The present manuscript summarizes the preclinical body of work applied to determine whether ABT-126 possesses the potential for abuse. To this end, the locomotor, functional observational, discriminative stimulus, reinforcing and dependenceproducing effects of ABT-126 were studied. All work was conducted over an approximately 6 year period of time across multiple sites both within and outside the company.
Methods and materials
All studies listed below were approved by the local Institutional Animal Care and Use Committee at the sites where they took place. Acute locomotor activity and drug discrimination studies were conducted at Abbott Park, North Chicago, IL. Physical dependence (Covance, Indianapolis, IN) and intravenous self-administration studies (MPI, Kalamazoo, MI) were conducted under Good Laboratory Practice (GLP) protocols. A summary of the doses, numbers of subjects, and routes of administration used in the present collection of experiments appears in Table 1 . All doses were chosen to emulate clinical exposures by > 3-fold, as outlined in the FDA Guidance Document.
Open field locomotor activity

Subjects
Forty-Eight male Sprague-Dawley rats weighing 240-260 g were used (N = Eight/treatment level). Animals were individually housed under a 12 h light/dark cycle in standard shoebox caging and given free access to food and water, except during experimental sessions.
Procedure
Rats were transported to the testing room and allowed to habituate for 1 h prior to testing. Rats were then placed into chambers (40 × 40 × 30 cm) for activity measures in an open field. Measurements were automatically recorded by a Versamax system (Columbus Instruments, Columbus, OH) which measures horizontal activity, total distance traveled, and vertical activity (rearing behavior) as previously described (Rueter et al., 2004) . Activity was assessed under dim light conditions (8-12 lx). Each rat was weighed, injected with the appropriate dose, and placed in the activity chambers that immediately began recording their activity. Activity was recorded in successive 5-min intervals over 60 min in the case of nicotine and 90 min for the longer-acting ABT-126.
ABT-126 and nicotine were dissolved in water. Rats were injected at a volume of 2 mL/kg i.p. (n = 8 animals per dosing group) with doses of 3 and 10 mg/kg of ABT-126, and 0.3 and 1 mg/kg nicotine. For analysis, total distance was used, and treatment groups were compared by 2-way repeated-measures ANOVA.
Physical dependence (CNS observations and locomotor activity)
Subjects
Sixty-four male Sprague-Dawley rats, weighing 213 to 233 g at randomization were used. They were assigned to one of four treatment levels: 0 mg/kg (vehicle), 1, 3, or 10 mg/kg ABT-126, p.o., dosed at a volume of 2 mL/kg. The p.o. route was chosen for this study because it is recommended by FDA to use the intended clinical route for such studies (FDA, 2017) . Amphetamine (15 mg/kg) was chosen as the (151) T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 positive control standard. Forty-eight rats were used as study animals (n = 12/group) and the remaining 16 rats (n = 4/group) were used as satellite animals for pharmacokinetic evaluations. Animals were allowed at least 3 days of acclimation prior to study initiation. Rats had ad libitium access to food (Harlan Teklad Global Diet -Rodent 2014) and tap water. Illumination in the testing room was maintained at 12 h light and 12 h dark.
CNS observations
CNS observations followed the basic methods as outlined by Moser (2000) . Evaluation was made of activity and arousal, posture, rearing, bizarre behavior, clonic and tonic movements, gait, mobility, stereotypy, righting reflex, response to stimulus (approach, click, tail pinch, and touch), palpebral closure, pupil response, piloerection, exophthalmus, lacrimation, salivation, and respiration.
The observations were initially employed on the day prior to drug dosing (in order to provide a pre-dose baseline) and on the following day at 3 h post-dosing (associated with the Tmax value), and again at 24 h post-dosing following the final dose.
Food intake and body weight were additionally recorded daily and analyzed separately.
Ambulatory and non-ambulatory locomotor activity
Animals were transported to a separate testing room for locomotor activity assessments. Activity was recorded in (40 × 40 × 30 cm) sound-and light-attenuated chambers (Kinder Scientific, Poway, CA) on the first and last (Day 21) day of dosing at approximately 80 min postdosing. In the withdrawal phase (Days 1-4 and 7), animals were tested at approximately the same time of day as during the dosing phase. Rats were assigned to a testing chamber pseudo-randomly in that the first animal of each group was assigned to a testing chamber followed by the second animal in each group. Recordings began individually once each animal was placed in the chamber and continued for 30 min. The relatively shorter duration of the measurements in the present study as opposed to the one described above was because the animals were to be repeatedly exposed to the locomotor arena and there was a desire to minimize the possibility of habituation to the apparatus, thus limiting potential measurement of drug effects. Movement was recorded via 32 photobeams (16 upper, 16 lower) where breakage of a photobeam indicated movement. Once all rats completed activity assessments, the rats were returned to their home cages and subsequently returned to the housing room. Activity was electronically captured and was reported as total ambulatory activity (Horozontal locomotor movement in cm) and total non-ambulatory activity (Vertical locomotor activity) for each day.
Drug exposure
Blood samples were collected from satellite animals (n = 16 total, n = 4/group/time point) at 60 min post-dose on study days 1, 4, 7 10, and 16. Approximately 600 μL whole blood samples were collected in tubes containing K 3 EDTA anticoagulant and processed for plasma within approximately 60 min of collection.
Data analysis
Body weight, and locomotor activity were analyzed by a two-way repeated measures ANOVA with a post hoc Dunnett's test for between group differences across time. For automated locomotor activity assessment analysis, group comparisons were made separately during the 3-week dosing phase and during the withdrawal phase by 2-way ANOVA followed by Bonferroni's t-tests. Food consumption was analyzed weekly by 1-way ANOVA group comparisons, with Dunnett's post hoc tests.
Nicotine and D-amphetamine drug discrimination
Subjects
Adult male Sprague-Dawley rats obtained from Charles River Laboratories, Inc., Portage, MI, were used for nicotine (n = 9) and Damphetamine drug discrimination (n = 12) studies. Following one week of quarantine, the rats were individually housed with free access to water under a 12-h light/dark cycle with training occurring during the light phase. When body weights reached approximately 400 g, food access was restricted and given daily following training/test sessions to maximize lever pressing for food reinforcement (45-mg 5TUL pellets, TestDiet, Richmond, IN). Body weights were initially reduced to 85-90% of free-feeding weight until lever press behavior was established and then maintained at a continually increasing estimate of their expected 85-90% weight by daily feeding of 13-18 g of rat chow.
Nicotine and D-amphetamine drug discrimination training
Training occurred daily, Monday through Friday, in standard twolever operant conditioning chambers (Coulbourn Instruments, Whitehall, PA) as previously described (Mohler et al., 2014) . Rats were first trained to press the levers for food pellets on a continuous reinforcement schedule (fixed ratio 1, FR 1), which was then gradually increased to FR10 over several sessions. Once responding on FR10 was established, drug discrimination training (per se) began. An errorless training procedure was used on the first eight drug discrimination sessions. For nicotine drug discrimination, rats were given a subcutaneous injection of saline or 0.4 mg/kg nicotine 10 min before each session. For D-amphetamine drug discrimination, rats received an intraperitoneal injection of saline or 0.3 mg/kg D-amphetamine 20 min before each session. Rats were immediately placed in the test chamber for a 10-min acclimation/absorption period in which the house light was extinguished and the retractable levers were inaccessible.
In the errorless training sessions, only the treatment-appropriate lever was extended and available following the 10-min acclimation, so that all responses were made on the lever associated with the injection given on that day. Once these errorless sessions were completed, discrimination training commenced daily on the standard procedure, which was similar to errorless sessions except that both levers were made available, and only presses on the lever assigned to the treatment condition resulted in food delivery. Completion of ten responses on the correct lever resulted in delivery of a food pellet to a receptacle located midway between the levers. Ten presses on the "incorrect" lever (i.e., the lever not assigned to the prior injection) resulted in a five-second blackout period in which the levers were retracted into the wall and the house light was extinguished. Lever assignments (Drug or Vehicle) were randomly distributed among groups.
Testing began only after all animals satisfied multiple response criteria. Rats were required to: 1) select the correct lever on the first completed FR10, and 2) make > 90% of total session responses on the correct lever for nine of ten consecutive sessions. In addition, rats were required to respond at a rate of lever pressing > 20 responses per minute, on average, before inclusion for testing.
2.3.3. Drug testing 2.3.3.1. Nicotine. All rats were tested on an experimenter-blinded, dose counterbalanced dose-response test. Nicotine doses of 0, 0.05, 0.1, 0.2 and 0.4 mg/kg by intraperitoneal route were tested first, in order to match the subsequent route of administration of ABT-126, thus minimizing the possibility that route of administration could serve as part of the drug cue. ABT-126 testing was initiated eleven days following the final day of i.p. nicotine testing. Following the ABT-126 dose-response assessment, the same doses of nicotine that were previously tested by the i.p. route were again tested by the subcutaneous route in order to establish whether differences in the cue strength were present as a result of the route of administration.
T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) ABT-126 was dissolved in sterile water. The pH of this compound varied from 4.25 at the lowest dose, down to 3.7 at the 8 mg/kg dose. ABT-126 was administered i.p. at doses of 0, 0.3, 1.0, 3.0, 6.0 and 8.0 mg/kg in a volume of 1 mL/kg of body weight, 30 min before each session started. The same doses of ABT-126 were tested in nicotine and D-amphetamine drug discrimination. DAmphetamine sulfate and nicotine hydrogen tartrate were dissolved in saline at all doses tested, and the pH ranged from 5.3-5.8.
Data analysis
Data were analyzed using Graph Pad Prism 4 (GraphPad Software, Inc., San Diego, CA). Statistical significance for the response rate measure was analyzed with ANOVA followed by Dunnett's multiple comparison tests between vehicle and drug doses. Full substitution for the nicotine or D-amphetamine training drug in terms of lever selection was defined as ≥ 80% responses on the drug-associated lever (Solinas et al., 2006; Nicholson and Balster, 2009 ). Vehicle-appropriate lever selection was defined as ≤20% response on the drug-associated level. Partial substitution was considered to occur when group means for lever choice were between 20% to 80% drug-lever selection. Lever choice measures were calculated for each rat by percent drug-lever choice over the whole session (total responses on "nicotine" or "amphetamine" lever/number responses on both levers × 100). An ED 50 value for full generalization curves was additionally calculated.
Intravenous self-administration
A total of 36 experimentally naïve male CD rats (approximately 7.5 weeks of age at arrival) were received equipped with chronic indwelling jugular vein catheters from Charles River Laboratories (Portage, MI, USA), were individually housed, and were acclimated for at least 1 week prior to any experimental training. All animals were given a detailed clinical examination prior to selection for the study.
Testing apparatus
Animals were trained and tested in sound-attenuating, standard two-lever operant chambers (Coulbourn Instruments; Whitehall, PA, USA) that were modified such that a tether and PE tubing could be routed through the top of the chamber via a swivel. The tubing was attached to a syringe pump located on the outside top of the chamber. Prior to placement in the operant chambers, animals were placed into a nylon jacket that fits snugly to protect the catheter connection but not impede movement. The catheter was then connected to the tubing. Following the sessions, the system was flushed with sterile saline, checked for leaks, and locked with 0.5 mL of either heparinized sterile 50% dextrose solution or heparinized sterile saline.
Procedure
Animals were initially trained, as previously described (Hudzik et al., 2013) , to respond under an FR1 schedule of reinforcement (i.e., each lever press resulted in food pellet delivery). Training sessions were a maximum of 30 min in duration, during which time approximately 50 food reinforcers were earned. Once the animals consistently responded under this FR1 schedule, the response requirements were increased until the animals consistently responded for food under at least a FR4 schedule of reinforcement, at which point the animals were then allowed to respond on the lever to obtain infusions of cocaine (0.56 mg/ kg/infusion) paired with the delivery of a single 45 mg food pellet per each infusion for one training session of 60 min maximum duration with a maximum of ten food/infusion rewards. Thereafter, food was discontinued, and the animals responded for drug deliveries only. As responding became more consistent during cocaine only training sessions, the response requirements were increased until the rats were required to complete ten responses (FR10) for each drug infusion. Sessions were terminated after a maximum of approximately 60 min in duration, with a maximum of ten infusion rewards allowed. Stable responding was defined as responding under a FR10 schedule for cocaine infusions with < 20% day-to-day variations over three consecutive sessions. Once each animal demonstrated stable responding for the maintenance dose of cocaine (0.56 mg/kg/infusion), test and substitution sessions were conducted. Test and substitution sessions were identical to training sessions, except for the drug or drug dose that was self-administered and because operant sessions terminated after 60 min with no restriction placed on the number of rewards attainable.
Drug testing
At least six animals were tested per treatment. All treatments were administered at a dose volume of 32 to 44 μL/infusion over a duration of 2.7 to 3.6 s/infusion. The saline control and positive control treatments were administered at 0 (saline), 0.1, and 0.56 mg cocaine/kg/ infusion. ABT-126 (in 50 mM phosphate buffered saline, pH 6.80 ± 0.05) was made available at 0 (phosphate buffer solution), 0.088, 0.177, 0.442, and 0.885 mg ABT-126/kg/infusion. Animals tested were exposed to each treatment condition once per day for three consecutive sessions.
At several points after the main study, dedicated bioanalysis was performed in study subjects, by non-contingent delivery of drug via the catheter, following the exact doses and temporal sequence as in the usual self-administration. Immediately following each final infusion, plasma samples were taken via tail vein and prepared as described, below.
Data analysis
ANOVA was used to compare treatment groups (means collapsed across the 3 days of drug availability), using Dunnett's post hoc evaluation to compare drug to vehicle groups.
Analysis of plasma levels of ABT-126
For each of the studies described above, plasma levels of ABT-126 were collected in sex and age-matched satellite animals, with the exception of the self-administration study (as described above). In the ABT-126 pharmacokinetic analyses, EDTA-treated blood samples were obtained from each of the tested animals at designed time points after drug administration. Plasma was separated by centrifuging at 4°C and stored frozen (~20°C) until thawed for analysis.
ABT-126 was separated from plasma using protein precipitation with acetonitrile. ABT-126 and the internal standards (not shown) were separated from each other and co-extracted contaminants on a 30 × 3 mm 3 μm Imtakt Scherzo SM C18 column with an acetonitrile: NH4Ac (10 mM, pH 5) mobile phase at a flow rate of 0.6 mL/min. Analysis was performed on a Sciex API5000™ Biomolecular Mass Analyzer with a turbo-ionspray source. Data was acquired in positive ion mode using MRM transitions of m/z 314.1 → 137.3 (ABT-126). ABT-126 and internal standard peak areas were determined using Sciex Analyst™ software. The concentration of each sample was calculated by least squares linear regression analysis of the peak area ratio (parent/ internal standard) of the spiked plasma standards versus concentration.
Results
Open field locomotor activity
The effects of administration of 3 and 10 mg/kg ABT-126 upon T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 locomotion over a 90-min period are shown in Fig. 1 , left panel. There was no main effect for treatment (F = 2, 21) = 0.97, P = 0.4 or for interaction (F(34, 357) = 0.8, P = 0.52). The time factor was, as expected, significant (F(17, 357) = 29, P < 0.0001). In contrast, nicotine's effects were more complex (Fig. 1, right panel) . While there was no main effect for dose (F(2, 27) = 0.99, P = 0.4), the interaction with time was significant ((F22, 297) = 4.7, P < 0.0001). Inspection of the curves suggested that nicotine suppressed ambulation early in the session and increased locomotion relative to control later in the session. A 2-way repeated measures ANOVA on the 2nd half of the session (minutes 30-60) revealed a main effect for dose (F(2, 27) = 6.9, P = 0.0004), with no interaction between factors.
CNS observations/physical dependence
CNS observations
The observations in the ABT-126 treated groups were limited to a few animals during the dosing and withdrawal phases of the study. CNS signs noted in the dosing phase of the study including increased reactivity and activity (3/12 rats on dosing days 1-7), some stereotypic head movements (4/12 rats on dosing days 1-4), and myoclonic jerking (3/12). Cessation of treatment produced some instances of tremor-like activity including myoclonic jerking and intermittent tremor (3/12 rats), but myoclonic jerking was also noted during dosing, indicating that it was not a withdrawal-related observation. The majority of ABT-126 treated rats appeared normal during both dosing and withdrawal phases of the study.
In contrast to ABT-126, amphetamine treated animals displayed a pattern of persistent clinical signs consisting of stereotypic head movements (up to 12/12 rats on dosing days 4-21), increased reactivity or activity (up to 11/12 rats on dosing days 1-21), and piloerection (up to 12/12 rats on dosing days 4-21). While some clinical signs were also noted during withdrawal from amphetamine, these were limited to a few rats and were not consistent with any pattern. The majority of the clinical signs during the withdrawal period were consistent with signs observed during dosing with the exception of decreased muscle tone, lethargy, and tremor-like behavior that was limited to 1-2 animals. All signs decreased in incidence over time following amphetamine treatment cessation.
3.2.1.1. Body weight and food consumption. ABT-126 did not alter food body weights with respect to vehicle-dosed animals, whereas as expected, amphetamine markedly decreased body weight with respect to control over time (Fig. 2 , left panel; F(2, 17) = 8.2, P < 0.0001; Dunnett's p < 0.05)). After dosing, body weight gain appeared to be greater in animals previously dosed with amphetamine; however, the body weights of the remaining animals were still significantly decreased through the last day of observation during withdrawal. For food consumption (Fig. 2, right panel) , only amphetamine-treated animals consumed less food than vehicle-treated animals with respect to each weekly average (Dunnett's, P < 0.05 except for week 2 of dosing). Consistent with the appearance of rapid weight gain in amphetamine-withdrawn animals, food consumption was significantly increased over this time period (Fig. 2) .
Ambulatory and non-ambulatory locomotor assessment
There were no effects of ABT-126 on horizontal activity at any time point (data not shown). The effects of ABT-126 on vertical photobeam breaks (i.e., rearing behavior) are shown in Fig. 3 (left panel) . There was a trend for ABT-126 to increase vertical activity (rearing behavior) during dosing (Day 1 -F(2,27) = 3.1, P = 0.06). However, a similar trend was also observed in the vehicle-treated controls following dosing.
Amphetamine produced the expected, significant locomotor stimulant effects during the dosing phase of the study, and produced particularly robust effects on vertical activity (Fig. 3, right panel) (Bonferroni's t = 6, P < 0.001) on both days during dosing. During the withdrawal phase, whereas vehicle-treated rats maintained a constant level of vertical activity, D-amphetamine treated rats reduced their vertical activity during the first 3 days of dosing (Day 3 -Bonferoni's t = 2.3, P = 0.02), returning to normal by 1 week after withdrawal. Similar overall patterns were seen in horizontal activity (data not shown).
Nicotine drug discrimination
Data from the nicotine dose-response portions of the study demonstrated robust, orderly control of discriminative stimulus effects by the training drug, nicotine (Fig. 4, left panel) . Complete generalization was noted at the training dose (0.4 mg/kg) as well as significant nicotine lever selection at the 0.1 and 0.2 mg/kg doses (Fig. 4, left panel) . Nicotine generalized with an ED 50 value of 0.07 mg/kg for overall discrimination. Response rate was not significantly reduced by the tested doses of nicotine. Nicotine demonstrated good stimulus control over lever choice behavior throughout testing and in dose-response studies conducted before and after ABT-126 testing. In these dose-response studies, the training dose of nicotine (0.4 mg/kg) resulted in nearly 100% nicotine lever selection with either intraperitoneal or subcutaneous administration. The ED 50 dose for response generalization was virtually identical for both nicotine dose-response studies that were conducted two to three months apart (ED 50 for i.p. dosing prior to the ABT-126 test was 0.075 mg/kg, while the ED 50 for s.c. dosing following drug testing was 0.073 mg/kg).
ABT-126 did not generalize to the nicotine training cue following doses of 0.18 mg/kg (Fig. 4, left panel) . Only two of eight rats at the 8 mg/kg ABT-126 dose (one rat failed to respond at this dose) selected T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 the nicotine lever on the first, unbiased trial, while no more than a single rat chose the nicotine lever first at any other doses. This, combined with the fact that group mean nicotine lever selection over complete sessions never exceeded 18%, indicates that ABT-126 does not produce an interoceptive stimulus similar to that from nicotine in rats. ABT-126 significantly reduced lever press response rates for food at doses of 6 and 8 mg/kg (Fig. 4 , right panel, inset), with respective percentage reductions from vehicle response levels of − 25% and − 43%, respectively Higher dose levels of ABT-126 were not tested because a near 50% response rate reduction had been achieved and at least two instances of behavioral disruption were observed. In a separate, satellite group of rats, the plasma concentration of ABT-126 after a 3 mg/kg dose was 116 ng/mL, while that following a 8 mg/kg dose of ABT-126 was 629 ng/mL (Table 1) .
d-Amphetamine drug discrimination
Robust, orderly discriminative control of behavior by the training drug was noted in the generation of the D-amphetamine dose-response curve (Fig. 5, left panel) . D-amphetamine had an ED 50 values of 0.16 mg/kg and 0.12 mg/kg in the pre-and post-test experiments, respectively, for overall discrimination. D-Amphetamine lever selection ranged from 80 to 100% at the training dose of 0.3 mg/kg. Response rate was not significantly reduced by the tested doses of D-amphetamine (right panel).
In contrast, ABT-126 did not generalize to the D-amphetamine training cue at the doses of 0.1-8 mg/kg (Fig. 5, right panel) , strongly suggesting dissimilarity to the D-amphetamine stimulus. Group mean Damphetamine lever selection never exceeded 19% of total lever choice at any dose, indicating that ABT-126 does not produce an interoceptive stimulus similar to that of D-amphetamine in rats. ABT-126 significantly reduced lever press response rates for food at doses of 6 and 8 mg/kg, with respective percentage reductions from vehicle response levels of − 28% and − 58% (Fig. 5, right panel, inset) . Higher dose levels were not tested because a > 50% response rate reduction had been achieved and several instances of behavioral disruption had been noted (mild whole body tremor, exophthalmus and stereotypic sniffing).
Intravenous self-administration
In rats trained to maintain stable levels of self-administration of 0.56 mg/kg/infusion of cocaine, the animals averaged approximately 21 injections of cocaine per session (Fig. 6, left panel) over each of three successive days of availability of this dose of drug. This corresponded to a total i.v. dose of approximately 12 mg/kg over each of the 1-h sessions. Relatively more injections of 0.1 mg/kg/infusion cocaine were self-administered (59 injections per session), which, nevertheless, resulted in lower exposures by the end of the hour-long session (5.9 mg/ kg, i.v.). In contrast, when vehicle was made available, subjects selfadministered an average of only 11-16 injections (for ABT-126′s and cocaine's vehicles, respectively) per 1-h session over three successive days, with the number of injections decreasing over successive days, indicating extinction of responding.
Similar to vehicle data, ABT-126 was self-administration an average of 7.2-15 injections over the dose range tested (Fig. 6, right panel) , indicating that ABT-126 does not behave as a positive reinforcer in rats at doses up to and including 0.885 mg/kg/infusion, a dose associated with plasma levels of 777 ng/mL (Table 1) at 15 min into the • Fig. 3 . Mean ( ± SEM) vertical activity in 30-min automated locomotor activity sessions during the dosing phase (days 1 and 21) and during the withdrawal phase (days 22, 23, 24-28) T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 administration sessions, which is well in excess of exposures necessary to demonstrate efficacy in animal models (Bitner et al., 2013) as well as highest clinical exposures. As with vehicle availability, the number of self-injections of ABT-126 declined over successive days of availability (Fig. 6 , right panel), indicating extinction of responding, which is typical when rewarding stimuli are removed.
Plasma concentrations across studies
In satellite animals within the reviewed studies, exposures were taken near to the time that testing was conducted and expressed as a multiple of the highest likely therapeutic exposure (Table 2 ). For each of the studies, greater than three times the highest expected therapeutic exposure was achieved, which aligns with FDA Guidance (FDA, 2017) . T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 
Discussion
Nicotine is a highly addictive substance, and its use in tobaccocontaining products contributes to millions of deaths per year worldwide (WHO, 2008) . Furthermore, its delivery in more pure forms such as 'vaping' serves to maintain its place in human addiction disorders (Palazzolo, 2013) . While nicotine is a relatively non-selective agonist across the multiple nicotinic receptor subtypes, including the α7, its addictive properties have been shown to result primarily, but perhaps not exclusively, from interaction with α4/β2 containing subunits of the receptor (Kenny and Markou, 2001 ). The possible involvement of α7 receptors and the potential addictive properties of a selective α7 receptor agonist had not yet been fully characterized. The present report is the first study to specifically address the question of the abuse potential of a selective agonist at α7 nAChRs.
As a therapeutic agent, ensuring that it does not carry the same liabilities as nicotine was vital in the development of ABT-126. A thorough evaluation of the abuse potential of a new chemical entity involves a step-wise series of inquiries and subsequent studies, if warranted. CNS penetration and activity are important initial criteria for such an evaluation, and this was undoubtedly the case for ABT-126. Comparison to appropriate standards in the methods employed in the present study (physical dependence, drug discrimination and intravenous self-administration), in addition to a careful evaluation of clinical adverse events, assists in decision-making toward whether clinical abuse potential studies are required. Critically, plasma concentrations in the various studies emulated and exceeded those likely to be used clinically by a minimum of 3-fold, thus ensuring that relevant doses were being tested. Overall, the present data do not indicate that ABT-126 has a likely potential for abuse, and suggest that other pharmacologically similar compounds in this class may also lack abuse potential.
ABT-126 (3-10 mg/kg) had little if any activity in locomotor activity tests, indicating a lack of either stimulant or depressant activity, in contrast to nicotine, which had biphasic effects upon locomotion. Additionally, there was no trend toward drug sensitization (an increase in drug effects after repeated administration that is characteristic of psychomotor stimulants), as the motor effects seen with ABT-126 were similar to that of the vehicle control group. This observation is important since, for nicotine itself, repeated administration often produces a greater locomotor response than a single dose (Elliott et al., 2004; Dwoskin et al., 1999) . Furthermore, upon cessation of dosing of ABT-126, there were no behavioral changes indicative of a withdrawal syndrome. By comparison, withdrawal from D-amphetamine resulted in some very subtle behavioral changes, as noted in clinical observations (increased reactivity) as wells as decreased vertical activity. It is noteworthy that a relatively high dose of D-amphetamine was required to evoke only subtle withdrawal signs. This is consistent with prior observations of, at best, subtle psychostimulant withdrawal signs in other laboratories such as vocalization (Covington and Miczek, 2003) or motor assessments (Schindler et al., 1994) . The subtle withdrawal signs noted following sub-chronic D-amphetamine, or of nicotine for that matter, may also speak to the relative limitations of the standard FOB and locomotor tests employed in the present study. For example, upon withdrawal from nicotine in humans, often disruption in cognition is noted (Ashare et al., 2014) . Hence, one limitation of the present approach is the limited sensitivity of the FOB to these types of withdrawal signs. The lack of nicotine-like discriminative stimulus effects of ABT-126 shown in the present study are in agreement with those in a previous report (Smith et al., 2007) . In that study, no generalization from the nicotine cue was noted for the α7 nAChR selective drug WO 01/ 60821A1, providing further evidence that α7 nAChRs provide little, if any, of the cuing properties of nicotine. It was also shown in the present study that it does not share discriminative stimulus effects with D-amphetamine. It may be of interest in future studies to attempt to use ABT-126 as a training drug in a drug discrimination study in order to more fully characterize its discriminative stimulus effects.
One of the most direct methods for addressing abuse potential of a new chemical entity is the intravenous self-administration paradigm, which is highly predictive of abuse potential in humans (O'Connor et al., 2011) . Animals that had been previously trained to self-administer cocaine intravenously did not self-administer appreciable levels of ABT-126 with respect to vehicle, strongly indicating that this α7 receptor agonist lacks any rewarding effects. This conclusion was further supported by the fact that during 3 consecutive days of availability of a * * Fig. 6 . Intravenous intake (number of injections) of cocaine (left panel) and of ABT-126 (right panel) in set of 6 or more rats trained to self-administer 0.56 mg/kg/injection cocaine HCl. Each dose of drug was made available on 3 successive days. * indicates significant difference (ANOVA) from vehicle injections following Dunnett's post-hoc comparisons. Other details are as described in the text. N = 6-8/dose group. T.J. Hudzik et al. Pharmacology, Biochemistry and Behavior 158 (2017) 22-31 range of doses of ABT-126, intake of the drug steadily decreased. That observation is congruous with the drug having a reward value similar to its vehicle. While this does not necessarily mean that the rats were unable to detect whether they had been given drug (and based upon exposure levels, there would likely be some subjective effects noted), it does indicate an indifference to whatever detectable effects there were. One caveat, however, in interpretation of these data is that animals were trained to self-administer cocaine, which is the standard employed in the laboratory conducting the studies. It would have been of interest to have also trained some rats to self-administer nicotine and then tested the substitution of ABT-126 in these nicotine-trained animals. This could be addressed in future studies. That being said, there is data suggesting that α7 nAChR agonists may work in opposition to nicotine's rewarding effects. Harenza and colleagues (Harenza et al., 2014) demonstrated that selective activation of the α7 nicotinic receptor could block the conditioned place preference engendered by nicotine, whereas α7 knockout mice were more sensitive to nicotine conditioned place preference. Further, Spiller et al. (Spiller et al., 2009 ) have shown that the selective α7 nicotinic receptor agonist, AR-R17779, did not alter intracranial self stimulation (ICSS) behavior, indicating a lack of rewarding effects at the doses tested. Similarly, Frietas et al., showed a similar lack of activity in ICSS with a different agonist, PNU 282987 (Freitas et al. 2015) . Overall, these data may suggest that not only do α7 nAChR agonists not appear to be reinforcing in their own right, they may potentially be useful in the treatment of nicotine dependence. The studies described in the present research report (locomotor activity, physical dependence, drug discrimination and intravenous self-administration) provide evidence that α7 nAChR selective agonists do not present a health risk related to addiction, abuse, or dependence.
